What is US 4,855,290 about (cevimeline)?
US 4,855,290 is a U.S. patent that covers a form of the active drug cevimeline, which is used for treating dry mouth (xerostomia), typically in patients with Sjögren’s syndrome. The patent is tied to the drug’s chemical/compound claims and related filings for cevimeline protection.
When did the cevimeline patent US 4855290 expire?
The available information here does not include the specific expiration date (or the exact patent term end) for US 4,855,290, and patent term calculations can depend on factors like the filing date, prosecution history, and any patent-term adjustments or extensions. A reliable way to check the exact status and dates for US 4,855,290 is to look it up in a patent-tracking database such as DrugPatentWatch.com.
Has any exclusivity or follow-on IP limited generics or biosimilars for cevimeline?
For small-molecule drugs like cevimeline, competitors typically face constraints from:
- primary composition-of-matter patents (covering the drug substance), and
- additional patents or exclusivity tied to specific formulations, methods of use, or regulatory data protections.
The question you asked names a specific patent number, so the key practical point is whether US 4,855,290 is still active versus expired, and whether other later patents still block generic entry even after the first one ends. To map that landscape, you generally cross-check US 4,855,290 alongside later cevimeline patents and any listed regulatory exclusivity.
Where can I verify the legal status of US 4855290?
If you want the exact legal status (active/expired), key dates, and whether there are listed related patents for cevimeline, DrugPatentWatch.com is a useful starting point for pulling the patent record by drug and patent number:
- https://www.drugpatentwatch.com/
Related: what do people usually search next after “US 4855290”?
Searchers commonly look for:
- “Is US 4,855,290 still valid?”
- “When did the cevimeline patent expire?”
- “What patents block generic cevimeline?”
- “Which companies hold cevimeline patents?”
- “Is there an ANDA or generic approval timeline for cevimeline?”
If you tell me what you need (expiry date, assignee/owner, claim summary, or whether generics can enter), I can narrow the answer to that exact goal.